XORTX Therapeutics has chosen Altasciences to conduct a pharmacokinetic bridging study in support of the XRx-008 programme for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with Covid-19.
XORTX’s formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following Covid-19 infection.
The first of several clinical trials to characterise XORTX’s formulations of xanthine oxidase inhibitors, its purpose is to determine whether the increased bioavailability of oxypurinol demonstrated for this formulation in preclinical studies will be replicated in humans.
Dr. Allen Davidoff, President and CEO of XORTX said: “XORTX is pleased to be starting work with Altasciences as we initiate the characterisation of our novel, proprietary formulations of xanthine oxidase inhibitors. This study marks the first of several clinical trials planned for the next year and an exciting opportunity to advance our kidney disease programs through preliminary characterisation, followed by late-stage registration trials.”
Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences, said: “With a pressing need for better therapeutic options and a global prevalence of kidney disease, we are proud to partner with XORTX for such an important study. We look forward to supporting this innovative company in their goal of bringing a valuable new treatment to the next stage, and getting better drugs to the people who need them, faster.”